1-8 of 8
eculizumab
Close
Sort by
Journal Articles

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Clinical Trials & Observations
Shruti Chaturvedi, Noor Dhaliwal, Sarah Hussain, Kathryn Dane, Harshvardhan Upreti, Evan M. Braunstein, Xuan Yuan, C. John Sperati, Alison R. Moliterno, Robert A. Brodsky
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1504–1512.
https://doi.org/10.1182/bloodadvances.2020003175
Published: 2021
Journal Articles

Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients

Clinical Trials & Observations
Jeroen D. Langereis, Bryan van den Broek, Sjoerd Franssen, Irma Joosten, Nicole M. A. Blijlevens, Marien I. de Jonge, Saskia Langemeijer
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3615–3620.
https://doi.org/10.1182/bloodadvances.2020002497
Published: 2020
Journal Articles

Interferon-complement loop in transplant-associated thrombotic microangiopathy

Clinical Trials & Observations
Sonata Jodele, Mario Medvedovic, Nathan Luebbering, Jenny Chen, Christopher E. Dandoy, Benjamin L. Laskin, Stella M. Davies
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1166–1177.
https://doi.org/10.1182/bloodadvances.2020001515
Published: 2020
Includes: Supplemental data
Journal Articles

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition

Clinical Trials & Observations
Sarah A. Lau-Braunhut, Hannah Stone, Griffin Collins, Sigbjørn Berentsen, Benjamin S. Braun, Matt S. Zinter
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3575–3578.
https://doi.org/10.1182/bloodadvances.2019000897
Published: 2019
Journal Articles

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion

Clinical Trials & Observations
Andrew Jay Portuguese, Brea Lipe
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3443–3446.
https://doi.org/10.1182/bloodadvances.2018027532
Published: 2018
Journal Articles

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial

Clinical Trials & Observations
Alexander Röth, Martin Bommer, Andreas Hüttmann, Dörte Herich-Terhürne, Nils Kuklik, Jan Rekowski, Veronika Lenz, Hubert Schrezenmeier, Ulrich Dührsen
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2543–2549.
https://doi.org/10.1182/bloodadvances.2018024190
Published: 2018
Journal Articles

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Clinical Trials & Observations
Alexander Röth, Scott T. Rottinghaus, Anita Hill, Eric S. Bachman, Jin Seok Kim, Hubert Schrezenmeier, Louis Terriou, Álvaro Urbano-Ispizua, Richard A. Wells, Jun Ho Jang, Austin G. Kulasekararaj, Jeff Szer, Rasha Aguzzi, Andrew I. Damokosh, Lori Shafner, Jong Wook Lee
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2176–2185.
https://doi.org/10.1182/bloodadvances.2018020644
Published: 2018
Includes: Supplemental data
Journal Articles

Use of the complement inhibitor Coversin to treat HSCT-associated TMA

Clinical Trials & Observations
Timothy H. J. Goodship, Fernando Pinto, Wynn H. Weston-Davies, Juliana Silva, Jun-ichi Nishimura, Miles A. Nunn, Ian Mackie, Samuel J. Machin, Liina Palm, Jeremy W. Pryce, Robert Chiesa, Persis Amrolia, Paul Veys
Journal: Blood Advances
Blood Adv (2017) 1 (16): 1254–1258.
https://doi.org/10.1182/bloodadvances.2016002832
Published: 2017
Includes: Supplemental data